A New Frontier
in Cardiovascular Research
Real-time insights into myocardial health through next-generation liquid biopsy
Extracellular vesicles are continuously released into the bloodstream by all cell types involved in cardiovascular function. They provide critical, real-time insight into endothelial dysfunction, myocardial injury, thrombogenicity, and vascular inflammation. This makes EVs ideal candidates for non-invasive, next-generation liquid biopsies
From Diagnosis to Prognosis
Transiently increases EV release from cardiomyocytes and endothelial cells, contributing to future cardiovascular events
EVs carrying renal-derived miRNAs are actively involved in the pathogenesis of heart failure
Endothelial EV profiles allow clinicians to distinguish between various endotypes of ischemia with non-obstructive coronary arteries
See how EVcount powers this research
Beyond Diagnostics: Targeted Drug Delivery
Beyond their role as biomarkers, EVs show immense promise as therapeutic tools. We are exploring their use as vehicles for targeted drug delivery directly to the heart, positioning EV technology at the forefront of precision cardiovascular medicine
Cargo analysis provides information on the cells of origin and on disease development. The common presence of EVs in body fluids makes them clinically interesting, providing minimally invasive and novel biomarkers from easily accessible body fluids or “liquid biopsies”
Single EV cargo analysis will facilitate early disease detection, prognosis assessment, and monitoring of treatment response, positioning EVs as a promising tool in precision medicine
EVcount is currently operating under the umbrella of Amsterdam University Medical Center to assess business feasibility. The activities are conducted under the supervision of the technology transfer office.
